<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068961</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/31</org_study_id>
    <nct_id>NCT04068961</nct_id>
  </id_info>
  <brief_title>New Strategies of Genetic Study of Patients With Oculocutaneous Albinism</brief_title>
  <acronym>GENALB</acronym>
  <official_title>New Strategies of Genetic Study of Patients With Oculocutaneous Albinism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <brief_summary>
    <textblock>
      The oculocutaneous albinism is an autosomal recessive condition associated with mutations in
      4 genes. In 20% of patients no mutation is identified. The optimization of genetic analysis
      methods and the search for new genes involved will help improve the diagnosis in these
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The oculocutaneous albinism is an autosomal recessive condition associated with mutations in
      4 genes. In 20% of patients no mutation is identified. The optimization of genetic analysis
      methods and the search for new genes involved will help improve the diagnosis in these
      patients.

      .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2010</start_date>
  <completion_date type="Actual">October 31, 2010</completion_date>
  <primary_completion_date type="Actual">October 31, 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of a genetic anomaly</measure>
    <time_frame>At the screening</time_frame>
    <description>Analysis by CGH (Comparative Genomic Hybridization) array : The Log2 values of the patient / reference fluorescence intensity ratios (Log2R) are -1 in the case of a heterozygous deletion, 0.5 in the case of heterozygous duplication and 0 in the absence of rearrangement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of a genetic mutation</measure>
    <time_frame>At the screening</time_frame>
    <description>By sequencing candidate genes : homozygotic cartography and candidate gene sequencing</description>
  </primary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Oculocutaneous Albinism</condition>
  <condition>Mutation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic analyzes</intervention_name>
    <description>Analysis by CGH array, homozygotic cartography and candidate gene sequencing</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples (2 blood tubes or 1 aliquot of DNA) are recorded in the DNA bank because were
      collected during the genetic consultation of these patients
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having been examined during a genetic consultation, with Oculocutaneous Albinism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Oculocutaneous albinism (diagnosis validated by a clinician at the initial genetic
        consultation and did not show mutations of the TYR, OCA2, TYRP1, SLC45A2 genes)

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny MORICE-PICARD, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CGH array chip</keyword>
  <keyword>Homozygosity mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albinism</mesh_term>
    <mesh_term>Albinism, Oculocutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

